A lzheimer's disease (AD) is a debilitating disease with progressive and serious effects on cognition, behavior, and ability to perform activities of daily living, resulting in caregiver burden and increased health care costs. 1 The current body of research surrounding AD and other dementias provides only a small amount of pharmacotherapy treatment guidance. A recently published practice guideline authored by the Joint Ameri can College of Physicians/American Academy of Family Physicians (ACP/AAF) Panel on Dementia concluded that U.S. Food and Drug Administration (FDA)-approved medications, including cholinesterase inhibitors (ChEIs, donepezil, galantamine, rivastigmine), and the neuropeptide-modifying agent memantine, provide "generally modest" improvements in global assessment as measured by the clinician-based impression of change (CIBIC). 1 The ACP/AAF review noted that in clinical trials, the statistically significant cognitive improvements associated with use of the medications were either "not clinically important" or of undetermined importance. 1 Once the decision has been made to initiate ChEI therapy, the ACP/AAF practice guidelines, as well as a Cochrane Review from 2006, conclude that all 3 ChEIs are equally effective. 1, 2 The ACP/AAF guidelines also support: (1) initiation of treatment based on an individualized assessment; (2) choice of agent based on tolerability, cost, ease of use, and adverse effects; and (3) that further research is urgently needed for treatment of dementia. 3 Study outcome measures included: (1) monthly prevalence of use in the first year of therapy initiation, (2) nonpersistence as measured by the occurrence of at least 1 gap in therapy of at least 30 days duration, (3) switching from the index drug to another ChEI, (4) total number of days on ChEI therapy, and (5) medication possession ratio (MPR). Mucha et al. also estimate the relationship between multiple measures of adherence and total 12-month all-cause (i.e., not specific to AD) health care expenditures. Unfortunately, despite the assessment of multiple measures of adherence, Mucha et al.'s retrospective claims database analysis adds little to our understanding of ChEI pharmacotherapy management.
To our knowledge, in addition to the work of Mucha et al., there have been 3 other studies of ChEI persistency. Although Mucha et al. found persistency differences in some endpoints, the other studies did not find differences in their primary endpoints. [4] [5] [6] As Mucha et al. note, an important difference between the previous studies and their own is that nonpersistency was defined in previous work as a 60-day gap in therapy, while Mucha et al. used a 30-day gap. Suh et al. followed patients newly diagnosed with AD and treated with either donepezil (n = 554) or rivastigmine (n = 229) for 1 year. 4 In both treatment groups, 47% of patients remained on therapy (P = 0.50); the mean (median) days on medication were 234 (312) for patients treated with rivastigmine and 235 (315) for patients treated with donepezil (P = 0.91). Suh et al. performed sensitivity analyses by varying the permissible gap to between 30 and 90 days. The 30-day gap persistency analysis found no statistically significant differences between the drugs, with persistency rates of 37% for rivastigmine and 40% for donepezil (P = 0.70).
Mauskopf et al. performed a similar comparison of patients treated with rivastigmine (n = 563) or donepezil (n = 1,871), using an administrative claims analysis but without restricting the sample to patients diagnosed with AD. Mauskopf et al. defined discontinuation as either a ≥ 60-day gap in therapy or a switch to another AD medication. 5 At 12 months after the index prescription, 37% of patients remained on donepezil versus 42% remaining on rivastigmine (P = 0.30). Finally, Singh et al. compared rivastigmine with donepezil in a California Medicaid program with persistency defined as a ≥ 60-day gap. 6 Persistency rates for donepezil were 32.7% (n = 15,128) and 39.3% for rivastigmine (n = 2,614; P value not reported). Although this difference is statistically significant using a Pearson chi-square test (P < 0.001), the study authors found that it was not statistically significant in a Kaplan-Meier analysis. 6 While there is no standard gap in therapy to define persistency, the 60-day gap is common in studies of the ChEIs and has clinical validity, because the ChEIs have titration periods of up to 8 weeks. The 60-day gap also accounts for real-life events, such as hospitalizations or periods of time when a patient uses half of the amount due to sideeffects or cost. 7 Nonetheless, when measuring persistence, using either a 30-day or a 60-day gap in therapy is justifiable, provided a sensitivity analysis is also performed to ensure that the findings are robust to the gap length. An analysis of the Mucha et al. data using a 60-day gap would have been important because the adherence and persistency findings in the Mucha et al. study at 30 days are inconsistent with those of previous research. Thus, Mucha et al. could be expected to have performed an analysis using a 60-day gap to replicate previous research with ChEI persistence; however, the sensitivity analysis was not done.
Another important shortcoming in the study reported by Mucha et al. is the lack of adjustment of the statistical analyses 1/N where N = number of comparisons) to declare significance. 8 Using the Bonferroni-adjusted P-value threshold, the 30-day gap persistency differences for the 3 agents, donepezil (36.5%), rivastigmine (32.0%), and galantamine (36.3%), did not achieve statistical significance (P = 0.042 for the comparison of donepezil with rivastigmine). In addition to this reduced number of statistically significant findings and the absence of practical significance in the persistency rates among the 3 ChEIs, the adherence rates defined as MPRs were not significantly different among the cholinesterase inhibitors: 74% for donepezil and galantamine and 71% for rivastigmine.
The monthly prevalence of use measurement is also fraught with statistical and methodological flaws, the most important of which is multiple comparisons between the ChEIs with no significance level adjustment. This analytical practice may remind the reader of the admonition that running a plethora of statistical comparisons will produce false-positive results. For example, using an alpha level of 0.05, the probability of making at least 1 "Type 1" (false positive) error after 20 trials is 65%. 9 The monthly prevalence analysis is notable for its inconsistency. Although the comparison of donepezil versus rivastigmine is statistically significant from month 5 forward, the other comparisons are significant, using the P < 0.05 standard, in certain months and not significant in other months. The authors make no attempt to explain these discrepancies. Furthermore, if the P value standard for statistical significance had been reduced to account for multiple comparisons, the number of statistically significant differences, other than in the comparisons of donepezil versus rivastigmine, would have been small, perhaps only in donepezil versus galantamine at month 9 and rivastigmine versus galantamine at month 5. These adherence and persistency results leave the reader wondering if there is an important finding here at all. And, second, what does it mean clinically?
We believe the implications of the Mucha et al. study are unclear for clinical practice today. For example, the authors fail to report that all 3 of the ChEIs are now available in a once-daily dosing option (galantamine ER and rivastigmine transdermal). Only the multiple daily-dose formulations of galantamine and rivastigmine were available during the study period in the report by Mucha et al. [10] [11] [12] Furthermore, in the text of the article, the authors identify the approved effective doses as 5 mg per day for donepezil, 16 mg-24 mg per day for galantamine, and 6 mg-12 mg per day for rivastigmine, but it is not clear from their data presentation if the authors used the lower end or upper end of the dose range for galantamine and rivastigmine. We do know that Mucha et al. used donepezil 5 mg as the starting and maximum dose despite the majority of clinical trials pushing the dose to 10 mg, 1 as well as 10 mg being the optimal dose recommended by the manufacturer per the Cochrane Review. 2 The Mucha et al. cholinesterase inhibitor-persistency analysis provides limited value to the current care of dementia patients. Other persistency analyses have found no difference between the cholinesterase inhibitors using a similar patient population. In the Mucha et al. study, there were no differences in all-cause health care costs among the 3 agents, and, unfortunately, costs related to the treatment of AD were not measured. Furthermore, we believe the use of the FDA-approved dose of donepezil for mildto-moderate dementia of 5 mg is not an appropriate measure of the true application of donepezil (i.e., the dose is often pushed to 10 mg in clinical practice if tolerated). Almost 80% of dementia patients are treated with donepezil, 13 and based on the majority of well-designed studies, there is no difference in persistency and adherence among the ChEIs. Yet, perhaps the most important limitation of the Mucha et al. findings is the limitation of the ChEI drugs themselves. Even if a patient is compliant with ChEI therapy, the evidence from clinical trial data seems to suggest that the outcomes of treatment, although statistically significant, are not clinically significant.
